Electra Therapeutics seeks a valuation of $977.6 million in its US IPO, aiming to raise $346.7 million.
The South San Francisco-based drug developer plans to list on Nasdaq under the ticker "ETRA," offering approximately 21.67 million shares at a price range of $14 to $16 per share. This listing comes amid a resurgence in biotech IPOs, with Electra Therapeutics intending to use the IPO proceeds to fund clinical trials for its lead experimental drug, ipsoprubart, and advance the development of its second candidate, ELA822.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Stock Tokenization: 2026 Market Overview and Top 5 Tokenized Stocks
-
2
JST (JUST) price surged to $0.11326, hitting a new 365-day high.
-
3
Aethir (ATH) Token Value Analysis: Decentralized Cloud Computing Project Potential and Risk Assessment
-
4
Standard Chartered Predicts XRP Could Reach $12.60 by 2028, Citing Unmet Catalysts
-
5
NEPT Coin Trading Guide: Distinguishing Between Similarly Named Projects and Their Respective Trading Channels
-
6
What is MEMO Coin? An Analysis of the Token, Transaction Memos, and Payment Platform
-
7
Bitcoin Trading Platforms and Mobile Apps Guide: Selection and Considerations
-
8
How will cyclical trends evolve after the Bitcoin halving?
-
9
LHC Coin: Analysis of Lightcoin Project Status and Development Prospects
-
10
What is WKAI? Wrapped KardiaChain (WKAI) Project Analysis and Risk Warning
Markets Today
Recommended Reading










